Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NuCana plc (NCNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5950-0.1350 (-4.95%)
At close: 04:00PM EST
2.5500 -0.05 (-1.73%)
After hours: 06:22PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close2.7300
Open2.7800
Bid2.5500 x 900
Ask2.6000 x 800
Day's Range2.5700 - 2.8000
52 Week Range1.8800 - 7.8300
Volume283,293
Avg. Volume1,969,057
Market Cap135.407M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-1.0060
Earnings DateNov 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,179.01
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NCNA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NuCana plc
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • GlobeNewswire

    NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update

    Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for the Treatment of Patients with Biliary Tract Cancer Announced Additional Encouraging Clinical Data for NUC-3373 and NUC-7738 at ESMO Multiple Near-Term Study Initiations and Data Announcements Expected EDINBURGH, United Kingdom, Nov. 18, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financia

  • GlobeNewswire

    NuCana to Present at the Jefferies 2021 London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference. Event: Jefferies 2021 London Healthcare ConferencePresentation Date: Wednesday, November 17, 2021Presentation Time: 4:20 PM GMT The presentation will be webcast live and available for replay under “Events & Presentatio

  • GlobeNewswire

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCanaEDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, inclu

Advertisement
Advertisement